SOUTH PLAINFIELD, N.J., Feb. 20, 2018 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the…Original Article
PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA’s Office of New Drugs
